CARLOS MANUEL
PANIZO SANTOS
Hospital Universitario 12 de Octubre
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (16)
2023
-
Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study
British Journal of Haematology, Vol. 202, Núm. 4, pp. 776-784
2022
-
Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study
Haematologica, Vol. 107, Núm. 11, pp. 2675-2684
2020
-
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier
Blood, Vol. 135, Núm. 13, pp. 996-1007
-
Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression
British Journal of Haematology, Vol. 189, Núm. 6, pp. 1064-1073
-
RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group
Annals of Hematology, Vol. 99, Núm. 4, pp. 799-808
2016
-
Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity
Immunologic Research, Vol. 64, Núm. 2, pp. 548-557
2015
-
Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: Results of the PRO-R-IPI study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 15, Núm. 7, pp. 398-403
2014
-
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: Results of a prospective, multicenter, phase II clinical trial
Haematologica
-
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: Results of a prospective, multicenter, phase II clinical trial
Haematologica, Vol. 99, Núm. 3, pp. 505-510
-
Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: A retrospective study of the Spanish experience
Annals of Hematology, Vol. 93, Núm. 9, pp. 1551-1558
-
First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial
The Lancet Haematology, Vol. 1, Núm. 3, pp. e104-e111
-
Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: A phase II GELTAMO trial
British Journal of Haematology, Vol. 167, Núm. 3, pp. 327-336
2012
-
Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain
Leukemia Research, Vol. 36, Núm. 6, pp. 709-714
2004
-
Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: A pharmacosurveillance study in Spain
Clinical Microbiology and Infection, Vol. 10, Núm. 9, pp. 785-790
2003
-
Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized, double-blind clinical trial
Journal of Thrombosis and Haemostasis, Vol. 1, Núm. 3, pp. 425-432